GQ 1005
Alternative Names: GQ-1005Latest Information Update: 17 Jun 2024
At a glance
- Originator Suzhou GeneQuantum Healthcare
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacokinetics, adverse events and efficacy data from a phase I trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 23 Nov 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT06154343)
- 18 Apr 2023 Phase-I clinical trials in Breast cancer (Parenteral) (Suzhou GeneQuantum Healthcare pipeline, April 2023)